Head Of Australia's Sigma Resigns In Face of Large Losses
This article was originally published in PharmAsia News
Executive SummarySigma Pharmaceuticals Managing Director Elmo de Alwis resigned his post in the wake of large losses recorded by the Australian drug maker. The director has held the post since Sigma went public in 2002, and led the firm into its acquisition of Arrow Pharmaceuticals in 2005. Company earnings have been on the decline for the past three years, leading to assertions the firm failed to disclose information key to potential investors. (Click here for more
You may also be interested in...
Once a pariah because of its price-gouging, the new approval represents a change of tack from Horizon.
Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He now answers to a newly appointed devices head who shares a common educational background but whose recent pharmaceutical role may unsettle the devices industry.
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.